What is Savara?
Savara operates at the intersection of pulmonary medicine and biotechnology, specifically targeting unmet needs in rare respiratory conditions. The company's flagship asset, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor currently in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). By utilizing the proprietary eFlow Nebulizer System, Savara aims to optimize drug delivery and therapeutic efficacy. The firm's strategic positioning is defined by its specialized management team, which leverages deep expertise in rare disease commercialization to bridge the gap between clinical discovery and regulatory approval, effectively mitigating the risks inherent in late-stage drug development.
How much funding has Savara raised?
Savara has raised a total of $227.5M across 11 funding rounds:
Stock Offering
$15.7M
Series B
$17.3M
Series C
$20M
Multiple Rounds
$70M
Stock Offering
$48.9M
Share Placement
$26.8M
Debt
$26.5M
Stock Issuance/Offering (2011): $15.7M supported by Undisclosed
Series B (2013): $17.3M featuring Keiretsu Forum Mid-Atlantic
Series C (2016): $20M backed by Haas Portman
Debt (2017): $15M with participation from Silicon Valley Bank
Stock Issuance/Offering (2017): $50M led by Undisclosed
Grant (2017): $5M supported by Cystic Fibrosis Foundation Therapeutics
Stock Issuance/Offering (2018): $48.9M featuring Undisclosed
Share Placement (2019): $26.8M backed by Bain Capital, Logos Capital, and EcoR1 Capital
Debt (2022): $26.5M with participation from Silicon Valley Bank
Key Investors in Savara
Bain Capital
A global private investment firm with extensive experience in life sciences, providing flexible capital solutions and operational expertise to drive long-term value in portfolio companies.
EcoR1 Capital
A San Francisco-based investment fund specializing in the biotech sector, focused on building long-term partnerships with entrepreneurs to advance therapeutic innovation.
Silicon Valley Bank
A premier financial partner for the innovation economy, providing specialized banking, credit, and investment services to high-growth life science and technology companies.
What's next for Savara?
Looking ahead, Savara is positioned to transition from a clinical-stage developer to a commercial-stage entity. The recent influx of capital provides the necessary runway to complete the Phase 3 trials for molgramostim and prepare for potential regulatory submissions. As the company moves toward commercialization, the focus will likely shift toward scaling manufacturing capabilities and establishing market access strategies for the aPAP patient population. Given the firm's history of securing diverse financing—ranging from venture capital and institutional stock offerings to strategic debt—Savara maintains a robust financial foundation to support its long-term objective of delivering transformative therapies to patients with limited treatment options.
See full Savara company page
